Testing CRP as one of the first diagnostic steps for the new COVID-19

Countries worldwide are fighting against the new COVID-19 outbreak. With a high virulence profile, this virus is flooding healthcare systems and arising fears and uncertainty between governments and people.

With an increase in hospitals influx treatment algorithms were developed in China to perform a swifter diagnosis of each patient suspected of having COVID-19. This algorithm considers CRP as being one of the early parameters that can help detect potential new cases of this infection. CRP, which usually does not increase dramatically with mild respiratory infections shows a significant increase in COVID-19 patients possibly due an increase in cytokines and lung alveoli damage. The early detection of a high CRP value can help HCP spot possible new cases and follow the treatment path in accordance with the applicable contingence plans and therefore help in the contention and mitigation of this new epidemic.

Through biosurfit products – spinit®, spinit® BC and spinit® CRP these parameters can be evaluated in a point-of-care instrument capable of providing clinically relevant and accurate results in approximately 5 minutes.

We believe POC diagnostic technology can improve swift assess from patients and HCP to diagnostic results and help contain and mitigate the impact of COVID.

[1] Zhang et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med 2020; https://doi.org/10.1016/S2213-2600(20)30071-0